阿托伐他汀对慢性肺心病缓解期患者肺功能及炎性因子的影响

目的 探讨阿托伐他汀对慢性肺心病缓（CPHD）解期患者肺功能及肺血管炎性因子的影响.方法 随机将118例CPHD缓解期患者分为对照组和观察组,每组均为59例,对照组采用常规治疗,观察组在常规治疗基础上加用阿托伐他汀.比较两组的临床疗效,治疗前后肺功能指标和肺血管炎性因子的变化.结果 观察组显效率和总有效分别达到49.15%和81.36%,显著高于对照组（P〈0.05）;治疗后观察组PAP、达到（44.61±6.80）mmHg,显著低于治疗前和对照组（P〈0.05）,FEV1、FEV1/FVC（%）分别为（0.93±0.19）L和（65.03±6.02）%,显著高于治疗前和对照组（P〈0.05）,两组FVC差异无显著性（P〉0.05）;治疗后观察组ET-1、IL-8和hs-CRP水平分别为（62.03±5.46）pg/ml、（51.54±7.66）ng/L和（1.57±0.40）mg/L,显著低于对照组治疗后水平（P〈0.05）.结论 常规治疗基础上联用阿托伐他汀可显著改善慢性肺心病缓解期患者的肺功能和临床症状,其机制可能与阿托伐他汀对肺血管炎性因子抑制作用有关.

Effect of atorvastatin on lung function and pulmonary vasculitis factors in patients with chronic pulmonary heart disease

Objective To investigate the effect of atorvastatin on lung function and pulmonary vaseulitis factors in patients with chronic pulmonary heart disease （CPHD）. Methods 118 CPHD patients at remission stage were randomly divided into the control group and the observation group with 59 cases in each group. All patients were given the conventional treatment, and the observation＇group was additionally treated with atorvastatin. The clinical efficacy and changes of pulmonary function and pulmonary vasculitis factors were ana- lyzed and compared between the two group before and after the treatment. Results The total effective rate was significantly higher in the observation group than in the control group （P 〈 O. 05 ）. The level of PAP in the observation group after the treatment reached 44.61 ± 6. 80 mmHg, which was significantly lower than before the treatment and that in the control group （ P 〈0.05 ）. The levels of FEVI and FEVj/FVC were increased more obviously in the observation group than in the control group （P 〈 0. 05 ）. There was no significant differ- ence on FVC between the two groups （P 〉 0. 05 ）. The levels of ET-1, IL-8 and hs-CRP were obviously lower in the observation group than in the control group （ P 〈 0. 05 ）. Conclusion The conventional therapy plus atorvastatin can significantly improve the lung function and clinical symptoms of CPHD patients, and the mechanism may be related to the inhibitory effect of atorvastatin on pulmonary vasculitis factors.